Biofilm proficient Bacillus subtilis prevents neurodegeneration in Caenorhabditis elegans Parkinson’s disease models via PMK-1/p38 MAPK and SKN-1/Nrf2 signaling.

Publication date: Mar 21, 2025

Parkinson’s disease (PD) is a no-curable neurodegenerative disease of pandemic distribution for which only palliative treatments are available. A hallmark of PD is injury to dopaminergic neurons in the substantia nigra pars compacta. Here, we report that Caenorhabditis elegans colonized by biofilm-forming Bacillus subtilis is resistant to injury of dopaminergic neurons caused by treatment with the PD-related neurotoxin 6-hydroxydopamine (6-OHDA). Biofilm-forming B. subtilis-colonized C. elegans display dopamine-dependent behaviors indistinguishable from those of 6-OHDA-untreated worms colonized by gut commensal E. coli OP50. In C. elegans PD model strains with early dopaminergic neuron decay or overexpressing human alpha-synuclein, biofilm-forming B. subtilis colonization had neuroprotective effects and prevents alpha-synulcein aggregation, respectively. The B. subtilis-controlled insulin/IGF-1 signaling (ILS), whose downregulation prevents aging-related PD, is not involved in protecting against 6-OHDA-related injury. We demonstrate that biofilm-forming B. subtilis activates PMK-1 (p38 MAPK)/SKN-1 (Nrf2) signaling, which protects C. elegans from 6-OHDA-induced dopaminergic neuron injury.

Open Access PDF

Concepts Keywords
Curable alpha-Synuclein
Hydroxydopamine alpha-Synuclein
Insulin Animals
Neurotoxin Bacillus subtilis
Parkinson Bacillus subtilis
Biofilms
Caenorhabditis elegans
Caenorhabditis elegans
Caenorhabditis elegans Proteins
Caenorhabditis elegans Proteins
Disease Models, Animal
DNA-Binding Proteins
DNA-Binding Proteins
Dopaminergic Neurons
Humans
Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinases
NF-E2-Related Factor 2
NF-E2-Related Factor 2
Nrf2 signaling
Oxidopamine
Oxidopamine
Parkinson Disease
Parkinson disease
Probiotics
Signal Transduction
Transcription Factors
Transcription Factors

Semantics

Type Source Name
disease MESH Parkinson’s disease
disease MESH neurodegenerative disease
drug DRUGBANK Dopamine
drug DRUGBANK Mecasermin
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
drug DRUGBANK L-Leucine
disease MESH oxidative damage
drug DRUGBANK Rotenone
disease MESH inflammation
disease MESH etiology
drug DRUGBANK Coenzyme M
pathway REACTOME Translation
disease MESH cancer
pathway KEGG Biofilm formation
pathway KEGG Quorum sensing
disease MESH death
drug DRUGBANK Ethanol
drug DRUGBANK Proline
drug DRUGBANK Oxygen
drug DRUGBANK Aspartame
pathway REACTOME Signal Transduction
disease MESH neuron degeneration
disease MESH Alzheimer’s disease
disease MESH starvation
drug DRUGBANK Lysozyme
drug DRUGBANK Water
drug DRUGBANK Ascorbic acid
drug DRUGBANK Magnesium sulfate
disease MESH alpha synucleinopathies
drug DRUGBANK Platinum
disease MESH bends
disease MESH Stemi
disease MESH palsy
disease MESH parkinsonism
drug DRUGBANK Gold
disease MESH weight loss
disease MESH overweight
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK Sirolimus
drug DRUGBANK Metformin
drug DRUGBANK Cadmium
drug DRUGBANK Angiotensin II
drug DRUGBANK Etoperidone
pathway REACTOME Reproduction
disease MESH Disease Models Animal
pathway KEGG Parkinson disease

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *